Pharmaceutical CAS 540737-29-9 Tofacitinib Citrate Raw Material Tofacitinib Citrate Powder Tofacitinib Citrate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Tofacitinib Citrate
• Product Name: Tofacitinib Citrate
• Name: Tofacitinib Citrate Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 540737-29-9
• Mf: C16h20n6o.C6h8o7
• MW: 504.497
• Melting Point: 201 C
• Storage Temperature: Room Temp
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical CAS 540737-29-9 Tofacitinib Citrate Raw Material Tofacitinib Citrate Powder Tofacitinib Citrate

Product Description

Product Details

Product Name	Esomeprazole Sodium
CAS NO.	161796-78-7
Purity	99%
Boiling Point	600 C at 760 mmHg
Appearance and shape	White powder

Esomeprazole Sodium is the sodium salt of the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.

Application&Function

1. Gastroesophageal reflux disease (GERD).
2. Treatment of erosive reflux esophagitis. 3. Patients who have been cured of esophagitis prevent recurrence of long-term maintenance.
4. The symptom control of gastroesophageal reflux disease (GERD) is combined with appropriate antimicrobial therapy to eradicate h. pylori.
5. Healing of duodenal ulcers associated with helicobacter pylori infection.
6. Prevent the recurrence of peptic ulcer associated with helicobacter pylori.

Specification